BNP Paribas Financial Markets
KLRS

BNP Paribas Financial Markets’s Kalaris Therapeutics KLRS Stock Holding History

BNP Paribas Financial Markets’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.76K Buy
652
+600
+1,154% +$5.33K ﹤0.01% 5350
2025
Q4 		$439 Sell
52
-89
-63% -$569 ﹤0.01% 5488
2025
Q3 		$815 Hold
141
– – ﹤0.01% 5257
2025
Q2 		$376 Buy
141
+14
+11% +$63 ﹤0.01% 5243
2025
Q1 		$1.02K Sell
127
-3,132
-96% -$30.7K ﹤0.01% 5066
2024
Q4 		$31.5K Buy
+3,259
New +$49.3K ﹤0.01% 4590

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BNP Paribas Financial Markets's KLRS Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Kalaris Therapeutics (KLRS) stake by 1,154% in Q1 2026, buying an estimated $5.33K and bringing the position to 652 shares worth $3.76K. The position accounts for ﹤0.01% of the portfolio, ranked #5350.

BNP Paribas Financial Markets first reported a position in KLRS in Q4 2024 and has held it in 6 quarters since. The position peaked at $31.5K in Q4 2024. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • BNP Paribas Financial Markets held 652 shares of Kalaris Therapeutics worth $3.76K as of Q1 2026.
  • BNP Paribas Financial Markets bought 600 Kalaris Therapeutics shares in Q1 2026, an estimated $5.33K.
  • Kalaris Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5350 holding.
  • BNP Paribas Financial Markets first reported a position in Kalaris Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Kalaris Therapeutics position peaked at $31.5K in Q4 2024.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.